Secukinumab Reduces Endothelial Dysfunction in Subjects with Moderate-to-Severe Plaque Psoriasis Over 52 Weeks: Results of the Exploratory CARIMA Study

Main Article Content

E von Stebut
K Reich
D Thaci
W Koenig
A Pinter
A Korber
T Rassaf
A Waisman
V Mani
D Yates
J Frueh
C Sieder
N Melzer
T Gori

Keywords

psoriasis, secukinumab, clinical trial

Abstract

Abstract not available.

 

Disclosures: Study sponsored by Novartis.

 

Copyright 2018 SKIN